Sell 2/27/2023Downgrade
Adhera Therapeutics, Inc. (ATRX) was downgraded to E+ from D- on 2/27/2023 due to a decline in the volatility index and total return index.

Sell 2/9/2023Upgraded
Adhera Therapeutics, Inc. (ATRX) was upgraded to D- from E+ on 2/9/2023 due to an increase in the volatility index.

Sell 1/20/2023Downgrade
Adhera Therapeutics, Inc. (ATRX) was downgraded to E+ from D- on 1/20/2023 due to a noticeable decline in the volatility index and total return index.

Sell 11/23/2022Downgrade
Adhera Therapeutics, Inc. (ATRX) was downgraded to D- from D on 11/23/2022 due to a substantial decline in the growth index and total return index. Earnings per share declined from -$0.2693 to -$0.5733, EBIT declined 22.05% from -$449 to -$548, and operating cash flow declined 20.68% from -$474 to -$572.

Sell 5/16/2022Upgraded
Adhera Therapeutics, Inc. (ATRX) was upgraded to D from E+ on 5/16/2022 due to an increase in the total return index.

Sell 5/13/2022Downgrade
Adhera Therapeutics, Inc. (ATRX) was downgraded to E+ from D on 5/13/2022 due to a decline in the total return index and volatility index.

Sell 5/4/2022Upgraded
Adhera Therapeutics, Inc. (ATRX) was upgraded to D from E+ on 05/04/2022.

Sell 5/1/2022Downgrade
Adhera Therapeutics, Inc. (ATRX) was downgraded to E+ from D on 05/01/2022.

Sell 4/21/2022Upgraded
Adhera Therapeutics, Inc. (ATRX) was upgraded to D from E+ on 04/21/2022.

Sell 4/20/2022Downgrade
Adhera Therapeutics, Inc. (ATRX) was downgraded to E+ from D on 4/20/2022 due to a substantial decline in the total return index and volatility index.

Sell 11/23/2021Upgraded
Adhera Therapeutics, Inc. (ATRX) was upgraded to D from D- on 11/23/2021 due to an increase in the total return index, volatility index and valuation index.

Sell 11/8/2021Downgrade
Adhera Therapeutics, Inc. (ATRX) was downgraded to D- from D on 11/8/2021 due to a large decline in the solvency index and valuation index. Debt to equity increased from -0.41 to -0.4.

Sell 1/5/2021Upgraded
Adhera Therapeutics, Inc. (ATRX) was upgraded to D from D- on 1/5/2021 due to an increase in the total return index and volatility index.

Sell 12/17/2020Downgrade
Adhera Therapeutics, Inc. (ATRX) was downgraded to D- from D on 12/17/2020 due to a decline in the total return index and volatility index.

Sell 11/5/2020Upgraded
Adhera Therapeutics, Inc. (ATRX) was upgraded to D from D- on 11/5/2020 due to an increase in the total return index and volatility index.

Sell 10/21/2020Downgrade
Adhera Therapeutics, Inc. (ATRX) was downgraded to D- from D on 10/21/2020 due to a decline in the total return index and volatility index.

Sell 10/1/2020Upgraded
Adhera Therapeutics, Inc. (ATRX) was upgraded to D from D- on 10/1/2020 due to an increase in the total return index and volatility index.

Sell 9/15/2020Downgrade
Adhera Therapeutics, Inc. (ATRX) was downgraded to D- from D on 9/15/2020 due to a decline in the solvency index, volatility index and total return index. The quick ratio declined from 0.01 to 0, and debt to equity increased from -0.49 to -0.47.

Sell 8/12/2020Upgraded
Adhera Therapeutics, Inc. (ATRX) was upgraded to D from D- on 8/12/2020 due to an increase in the volatility index and total return index.

Sell 7/28/2020Downgrade
Adhera Therapeutics, Inc. (ATRX) was downgraded to D- from D on 7/28/2020 due to a decline in the volatility index.

Sell 7/9/2020Upgraded
Adhera Therapeutics, Inc. (ATRX) was upgraded to D from D- on 7/9/2020 due to an increase in the volatility index.

Sell 7/6/2020Downgrade
Adhera Therapeutics, Inc. (ATRX) was downgraded to D- from D on 7/6/2020 due to a decline in the volatility index and total return index.

Sell 6/19/2020Upgraded
Adhera Therapeutics, Inc. (ATRX) was upgraded to D from D- on 6/19/2020 due to an increase in the volatility index, growth index and total return index.

Sell 5/1/2020Downgrade
Adhera Therapeutics, Inc. (ATRX) was downgraded to D- from D on 5/1/2020 due to a significant decline in the solvency index, efficiency index and volatility index. Total capital declined 6,601.47% from -$68 to -$4.56M, the quick ratio declined from 0.3 to 0, and net income declined 59.78% from -$2.56M to -$4.08M.

Sell 8/19/2019Upgraded
Adhera Therapeutics, Inc. (ATRX) was upgraded to D from D- on 8/19/2019 due to a significant increase in the efficiency index, growth index and volatility index. Total revenue increased 2,175.86% from $2.9 to $66, and operating cash flow increased 30.94% from -$2.09M to -$1.44M.

Sell 11/20/2018Upgraded
Adhera Therapeutics, Inc. (ATRX) was upgraded to D- from E+ on 11/20/2018 due to an increase in the efficiency index, growth index and solvency index. EBIT increased 20.78% from -$3.77M to -$2.99M, and operating cash flow increased 16.86% from -$3.8M to -$3.16M.

Sell 8/23/2018Downgrade
Marina Biotech, Inc. (MRNA) was downgraded to E+ from D- on 8/23/2018 due to a decline in the efficiency index, total return index and growth index. Operating cash flow declined 6,380.38% from -$58.6 to -$3.8M, net income declined 241.47% from -$1.36M to -$4.65M, and earnings per share declined from -$0.1294 to -$0.4295.

Sell 6/29/2018Downgrade
Marina Biotech, Inc. (MRNA) was downgraded to D- from D on 6/29/2018 due to a decline in the total return index and volatility index.

Sell 5/18/2018Upgraded
Marina Biotech, Inc. (MRNA) was upgraded to D from D- on 5/18/2018 due to an increase in the valuation index and efficiency index. Net income increased 54.52% from -$2.99M to -$1.36M.

Sell 8/1/2017Upgraded
Marina Biotech, Inc. (MRNA) was upgraded to D- from E+ on 8/1/2017 due to an increase in the valuation index.

Sell 5/19/2017None
Adhera Therapeutics, Inc. (ATRX) was downgraded to E+ from U on 05/19/2017.